Early Interim 18f-FDG PET In Hodgkin's Lymphoma: Evaluation on 304 Patients

• Published in: Blood 2010-11, Vol.116 (21), p.3879-3879
• Main Authors: Zinzani, Pier Luigi, Rigacci, Luigi, Stefoni, Vittorio, Broccoli, Alessandro, Puccini, Benedetta, Gandolfi, Letizia, Fanti, Stefano, Castagnoli, Antonio, Pellegrini, Cinzia, Montini, Gian Carlo, Quirini, Federica, Antognoli, Giulia, Vaggelli, Luca, Derenzini, Enrico, Argnani, Lisa, Ambrosini, Valentina, Agostinelli, Claudio, Pileri, Stefano A., Bosi, Alberto, Baccarani, Michele
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V116.21.3879.3879

Abstract 3879 The use of early (interim) positron emission tomography (PET) restaging during front-line therapy in Hodgkin's lymphoma (HL) has considerably increased in clinical practice as an early recognition of treatment failure allows patients to be addressed to more intensive treatment regimens. Between June 1997 and June 2009, 304 newly-diagnosed Hodgkin's lymphoma patients (147 early-stage and 157 advanced-stage) were treated with the ABVD regimen at two Italian institutions. Patients underwent to a PET staging and restaging at baseline, after 2 cycles of therapy and at the end of the treatment. 53 patients showed a positive interim PET and only 13/53 (24.5%) achieved a complete response (CR), whereas 251 patients showed a negative PET and 231/251 (92%) remained in CR. Comparison between interim PET-positive and interim PET-negative patients indicated a significant association between PET findings and 9-year progression-free survival (p=0.0000) and 9-year overall survival (p=0.0000), with a median follow-up of 31 months. Among the early-stage patients, 19 had a positive interim PET and only 4 (21%) achieved a CR; among the 128 negative interim PET patients, 122 (97.6%) obtained a CR. In the advanced-stage subset, 34 patients showed a persistently positive PET (with only 9/34, 26.4% in CR), whereas 123 showed a negative interim PET, with 109 (88.6%) remaining in CR. Our results confirm the role of early PET as a significant step forward for the management of both early and advanced-stage HL patients, offering the potential for an immediate switch to high-dose treatments, if required. No relevant conflicts of interest to declare.